AI Verdict
ICFI has stronger fundamentals based on our AI analysis.
ICFI vs IBRX Fundamental Comparison
| Metric | ICFI | IBRX |
|---|---|---|
| Revenue | $1.9B | $113.3M |
| Net Income | $91.6M | $-351.4M |
| Net Margin | 4.9% | -310.2% |
| ROE | 8.9% | N/A |
| ROA | 4.5% | -70.0% |
| Current Ratio | 1.27x | 5.10x |
| Debt/Equity | 0.39x | N/A |
| EPS | $4.95 | $-0.38 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ICFI vs IBRX: Frequently Asked Questions
Is ICFI or IBRX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), ICFI has stronger fundamentals. ICFI is rated HOLD (58% confidence) while IBRX is rated STRONG SELL (92% confidence). This is not investment advice.
How does ICFI compare to IBRX fundamentally?
ICF International, Inc. has ROE of 8.9% vs ImmunityBio, Inc.'s N/A. Net margins are 4.9% vs -310.2% respectively.
Which stock pays higher dividends, ICFI or IBRX?
ICFI has a dividend yield of N/A or no dividend while IBRX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ICFI or IBRX for long term?
For long-term investing, consider that ICFI has HOLD rating with 58% confidence, while IBRX has STRONG SELL rating with 92% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ICFI vs IBRX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ICFI vs IBRX, the AI consensus favors ICFI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.